The "gradual decline" group (approximately 40-50% of users) represents modal experience where benefits slowly regress toward pre-treatment baseline over 4-8 months, typically affecting users who completed shorter treatment courses (2-4 months), used lower concentrations or inconsistent application, possessed moderate to severe baseline skin damage requiring ongoing support, maintained adequate but not optimal complementary skincare, experienced significant lifestyle stressors affecting skin health including poor sleep or high stress, and faced genetic or age-related collagen production limitations
Accessed December 11, 2024 via [18] Numerator GLP-1 Hub
Most cases are triggered by mutations within two specific genes, the NRAS and the BRAF
A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II) Obesity (Silver Spring) 2013;21(5):935943
N Engl J Med 2025;392:777-87.ArticlePubMed 118
Human studies in other chronic pain conditions, including neuropathic pain syndromes, have shown measurable pain reduction and improved function with GLP-1 therapy
